What factors drove the changes in Zoetis's revenue and profit?

What is the revenue and EPS growth rate for Zoetis year over year?

What is Zoetis's latest dividend and current dividend yield?

What is the market's earnings forecast for Zoetis next quarter?

What guidance did Zoetis's management provide for the next earnings period?

What were the key takeaways from Zoetis's earnings call?

What is Zoetis's gross profit margin?

What does Zoetis do and what are its main business segments?

- **Revenue Growth**: 4% organic operational, driven by Companion Animal and Livestock. 
- **Challenges**: OA pain franchise down 11%, competitive dermatology pressure. 
- **Innovation**: 2026 launches of Lenivia and Portela to expand OA market. 
- **Margins**: Gross margin 71.6%, cost control maintained. 
- **Guidance**: 2025 organic 5.5-6.5%, 2026 focus on price, alternative channels.

**【CEO Summary Section】**
- Reported $2.4 billion in revenue, with 4% organic operational growth driven by Companion Animal and Livestock segments. 
- OA pain franchise declined 11% operationally, while Simparica Trio grew 7% and Key Dermatology expanded 3%. 
- Global Livestock revenue rose 10% organically, supported by poultry and vaccine growth. 
- Full-year organic operational revenue guidance revised to 5.5-6.5%, with adjusted net income growth narrowed to 5.5-7%. 

**【CFO Financial Commentary】**
- Adjusted gross margin improved to 71.6%, benefiting from price increases and MFA divestiture. 
- U.S. Companion Animal flat, with Simparica Trio up 2% and OA pain mAbs down 26%. 
- International Companion Animal grew 4%, led by Simparica Trio (32%) and Apoquel (15%). 
- Full-year revenue guidance updated to $9.1-9.47 billion, reflecting macro and operational trends. 

**【Q&A Highlights】**
- Competitive dynamics in dermatology: Zenrelia launch caused 1% share loss, but short-lived. 
- Librela stabilization signs, with 2026 growth expected via Phase IV research and specialist engagement. 
- New products: Lenivia (3-month OA relief) and Portela (feline pain) set for 2026 launches. 
- Alternative channels (home delivery) grew 21%, offsetting clinic visit declines. 
- 2026 outlook: focus on Livestock expansion, price hikes (2-4%), and innovation pipeline execution.

ZTS

ZTS fundamentals

You can ask Aime